Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...

OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...

HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

SHANGHAI, China I 10, 2025 I On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products ...

The company has assembled a team that hails from DeepMind and Microsoft, AI in drug discovery specialist Exscientia, genomics ...